文献

J-GLOBAL ID：201102276807930414   整理番号：11A1416495

病勢のDAS28スコアはトシリズマブにより治療した関節リウマチ患者の緩和導入の過剰評価の可能性

Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index

著者 (14件)： KAWASHIRI Shin-ya (Nagasaki Univ., Nagasaki, JPN) ,  KAWAKAMI Atsushi (Nagasaki Univ., Nagasaki, JPN) ,  IWAMOTO Naoki (Nagasaki Univ., Nagasaki, JPN) ,  FUJIKAWA Keita (Isahaya Health Insurance General Hospital, Nagasaki, JPN) ,  ARAMAKI Toshiyuki (Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, JPN) ,  TAMAI Mami (Nagasaki Univ., Nagasaki, JPN) ,  YAMASAKI Satoshi (Nagasaki Univ., Nagasaki, JPN) ,  NAKAMURA Hideki (Nagasaki Univ., Nagasaki, JPN) ,  UEKI Yukitaka (Sasebo Chuo Hospital, Sasebo, JPN) ,  MIGITA Kiyoshi (NHO National Nagasaki Medical Center, Nagasaki, JPN) ,  MIZOKAMI Akinari (Nagasaki Municipal Hospital, Nagasaki, JPN) ,  ORIGUCHI Tomoki (Nagasaki Univ., Nagasaki, JPN) ,  AOYAGI Kiyoshi (Nagasaki Univ. Graduate School of Biomedical Sci., Nagasaki, JPN) ,  EGUCHI Katsumi (Nagasaki Univ., Nagasaki, JPN)
資料名： Modern Rheumatology  (Modern Rheumatology)
巻： 21  号： 4  ページ： 365-369  発行年： 2011年 
JST資料番号： L5142A  ISSN： 1439-7595  資料種別： 逐次刊行物 (A)
記事区分： 原著論文  発行国： イギリス (GBR)  言語： 英語 (EN)

抄録/ポイント： トシリズマブ(TCZ)は抗IL-6の受容体の結合を遮断するヒ...

シソーラス用語： *モノクローナル抗体 ,...
準シソーラス用語： DAS28-ESR ,...

ログイン（無料）して見る     続きはJDreamIII（有料）にて  {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=11A1416495&from=J-GLOBAL&jstjournalNo=L5142A") }}

分類 (1件)： 運動器系疾患の薬物療法  (GG05020D)

物質索引 (1件)： CRP

引用文献 (15件)：

• MIHARA, M. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005, 5, 1731-1740
• NISHIMOTO, N. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI) : evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007, 66, 1162-1167
• NISHIMOTO, N. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI) : significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009, 19, 12-19
• SMOLEN, JS. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study) : a double-blind, placebo-controlled, randomised trial. Lancet. 2008, 371, 987-997
• GENOVESE, MC. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs : the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008, 58, 10, 2968-2980

タイトルに関連する用語 (9件)： DAS28 ,  スコア ,  トシリズマブ ,  治療 ,  関節リウマチ ,  患者 ,  緩和 ,  評価 ,  可能性